- First quarter reported net sales decreased 2.2 percent
year-over-year to $1.54 billion, and internal sales decreased 2.8
percent.
- Returned $73.3 million to shareholders in first quarter of
fiscal 2025 through dividends and share repurchases.
- Delivered first quarter GAAP earnings of $0.15 per diluted
share and adjusted earnings1 of $0.24 per diluted share; both GAAP
and adjusted earnings1 were negatively impacted by the
cybersecurity attack on Change Healthcare compared to the prior
year.
- Reaffirms fiscal 2025 GAAP earnings guidance range of $2.00
to $2.10 per diluted share and adjusted earnings1 guidance range of
$2.33 to $2.43 per diluted share.
Patterson Companies, Inc. (Nasdaq: PDCO) today reported
operating results for its fiscal 2025 first quarter ended July 27,
2024.
"Our first quarter results fell short of our expectations,
primarily due to the greater than anticipated impact of the Change
Healthcare cybersecurity attack on the value-added services
category in our dental segment, along with lower sales in our
companion animal business and the timing of certain corporate
expenses," said Don Zurbay, President and CEO of Patterson
Companies. "In light of these factors and against the backdrop of a
challenging macroeconomic environment, we are taking dedicated cost
and management actions across Patterson to deliver on our financial
plan for fiscal 2025, and maintaining a strategic focus on
supporting our customers with the deep and differentiated
value-proposition they expect from us."
First Quarter Fiscal 2025 Results
Consolidated net sales were $1.54 billion (see attached Sales
Summary for further details), a decrease of 2.2 percent compared to
the same period last year. Internal sales, which are adjusted for
the effects of currency translation and the net impact of an
interest rate swap, decreased 2.8 percent over the prior year
period.
Reported net income attributable to Patterson Companies, Inc.
for the first quarter of fiscal 2025 was $13.7 million, or $0.15
per diluted share, compared to $31.2 million, or $0.32 per diluted
share, in the first quarter of fiscal 2024. Adjusted net income1
attributable to Patterson Companies, Inc., which excludes deal
amortization totaled $21.0 million for the first quarter of fiscal
2025, or $0.24 per diluted share, compared to $38.6 million, or
$0.40 per diluted share, in the first quarter of fiscal 2024. The
year-over-year decrease in reported and adjusted net income
attributable to Patterson Companies, Inc. in the first quarter of
fiscal 2025 is related to lower retail sales and operating margins
in both business segments and the continued negative impact of the
widely reported cybersecurity attack on vendor Change Healthcare,
within the value-added services category of the dental segment.
Both reported and adjusted net income in the fiscal 2025 first
quarter were negatively impacted by the cybersecurity attack on
Change Healthcare compared to the prior year period.
Patterson Dental
Reported net sales in the Dental segment for the first quarter
of fiscal 2025 were $550.4 million. Internal sales decreased 2.8
percent compared to the fiscal 2024 first quarter. Internal sales
of consumables decreased 2.1 percent year-over-year. Excluding the
deflationary impact of certain infection control products, internal
sales of consumables decreased 1.7 percent year-over-year. Compared
to the prior year period, internal sales of equipment decreased 2.4
percent. Internal sales of value-added services decreased 6.7
percent compared to the prior year period, primarily due to the
negative impact of the cybersecurity attack on Change
Healthcare.
Patterson Animal Health
Reported net sales in the Animal Health segment for the first
quarter of fiscal 2025 were $982.4 million. Internal sales declined
2.8 percent compared to the fiscal 2024 first quarter. Compared to
the prior year period, internal sales of consumables declined 3.0
percent, equipment decreased 3.8 percent and value-added services
increased 8.3 percent.
Balance Sheet and Capital Allocation
During the first quarter of fiscal 2025, Patterson Companies
used $285.0 million of cash from operating activities and collected
deferred purchase price receivables of $271.8 million, using $13.1
million in cash, compared to using $11.4 million during the first
quarter of fiscal 2024. Free cash flow1 (see definition below and
attached free cash flow table) during the first quarter of fiscal
2025 improved by $1.8 million compared to the first quarter of
fiscal 2024.
In the first quarter of fiscal 2025, Patterson Companies
declared a quarterly cash dividend of $0.26 per share, returning
$23.3 million in cash dividends to shareholders. Also, under a
prior repurchase authorization, the company repurchased
approximately $50.0 million of shares during the fiscal first
quarter. At of the end of the first quarter of fiscal 2025,
Patterson had approximately $450 million of share repurchase
authority remaining on its current share repurchase authorization.
During the first quarter of fiscal 2025, Patterson Companies
returned $73.3 million to shareholders in the form of cash
dividends and share repurchases.
Fiscal 2025 Guidance
Patterson Companies today reaffirmed its fiscal 2025 earnings
guidance, which is provided on both a GAAP and non-GAAP adjusted1
basis:
- GAAP earnings are expected to be in the range of $2.00 to $2.10
per diluted share.
- Non-GAAP adjusted earnings1 are expected to be in the
range of $2.33 to $2.43 per diluted share.
- Our non-GAAP adjusted earnings1 guidance excludes the
after-tax impact of:
- Deal amortization expenses of approximately $29.1 million
($0.33 per diluted share).
Our guidance reflects the strength of our business and
competitive positioning as well as completed and previously
announced acquisitions. It does not include the impact of unplanned
share repurchases, potential future acquisitions or similar
transactions, impairments, restructuring and integration expenses
not previously publicly disclosed, or amortization expense of
acquired intangible assets. Our guidance assumes North American and
international end market conditions consistent with current market
conditions.
1Non-GAAP Financial Measures
The term “internal sales” used in this release represents net
sales adjusted for the effects of currency translation and the net
impact of an interest rate swap. Foreign currency impact represents
the difference in results that is attributable to fluctuations in
currency exchange rates the company uses to convert results for all
foreign entities where the functional currency is not the U.S.
dollar. The company calculates the impact as the difference between
the current period results translated using the current period
currency exchange rates and using the comparable prior period’s
currency exchange rates. The company believes the disclosure of net
sales excluding the impact of foreign currency and an interest rate
swap provides useful supplementary information to investors in
light of fluctuations in these variables that are independent of
our period-over-period performance.
The term “free cash flow” used in this release is defined as net
cash used in operating activities less capital expenditures plus
the collection of deferred purchase price receivables.
The Reconciliation of GAAP to non-GAAP Measures table appearing
behind the accompanying financial information is provided to adjust
reported GAAP measures, namely net sales, gross profit, operating
expenses, operating income, other income (expense), net, income
before taxes, income tax expense, net income, net loss attributable
to noncontrolling interests, net income attributable to Patterson
Companies, Inc., and diluted earnings per share attributable to
Patterson Companies, Inc. for the impact of deal amortization and
an interest rate swap along with any related tax effects of these
items.
- Deal amortization represents non-cash intangible amortization
expense, primarily related to the acquisition of Animal Health
International.
- Interest rate swap -- Our customer financing net sales include
the impact of changes in interest rates on deferred purchase price
receivables, as the average interest rate in our contract portfolio
may not fluctuate at the same rate as interest rate markets,
resulting in an increase or reduction of gain on contract sales. We
enter into an interest rate swap to hedge a portion of the related
interest rate risk. These agreements do not qualify for hedge
accounting, and the gains or losses on an interest rate swap are
reported in other income and expense in our condensed consolidated
statements of operation and other comprehensive income. We present
a non-GAAP adjustment to reclassify the mark-to-market adjustment
on the interest rate swap from other income (expense) to net sales
to align the swap impact with the impact on customer financing net
sales. We believe adjusted net sales, adjusted gross profit and
adjusted operating income, which include the gains and losses on
the interest rate swap, provides additional comparability from
period to period because they present the impact of interest rate
fluctuations, net of the mark-to-market swap adjustment, within
adjusted net sales. We note the net impact of interest rate
fluctuations has a minimal impact on net income.
Management believes that these non-GAAP measures may provide a
helpful representation of the company’s performance and enable
comparison of financial results between periods where certain items
may vary independent of business performance. These non-GAAP
financial measures are presented solely for informational and
comparative purposes and should not be regarded as a replacement
for corresponding, similarly captioned, GAAP measures.
First Quarter Conference Call and Replay
Patterson Companies’ fiscal 2025 first quarter conference call
will start at 8:30 a.m. Eastern today. Investors can listen to a
live webcast of the conference call at www.pattersoncompanies.com.
The conference call will be archived on the Patterson Companies
website. A replay of the fiscal 2025 first quarter conference call
can be heard for one week at 1-800-770-2030 and by providing the
Conference ID 67281 when prompted.
About Patterson Companies Inc.
Patterson Companies Inc. (Nasdaq: PDCO) connects dental and
animal health customers in North America and the U.K. to the latest
products, technologies, services and innovative business solutions
that enable operational and professional success. Our comprehensive
portfolio, distribution network and supply chain is equaled only by
our dedicated, knowledgeable people who deliver unrivalled
expertise and unmatched customer service and support.
Learn more: pattersoncompanies.com
This press release contains, and our officers and
representatives may from time to time make, certain
“forward-looking statements” within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995, including statements regarding future financial performance,
and the objectives and expectations of management. Forward-looking
statements often include words such as “believes,” “expects,”
“anticipates,” “estimates,” “intends,” “plans,” “seeks” or words of
similar meaning, or future or conditional verbs, such as “will,”
“should,” “could” or “may.”
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results and financial
condition may differ materially from those indicated in the
forward-looking statements. Therefore, you should not place undue
reliance on any of these forward-looking statements.
Any number of factors could affect our actual results and cause
such results to differ materially from those contemplated by any
forward-looking statements, including, but not limited to, the
following: our dependence on suppliers to manufacture and supply
substantially all of the products we sell; potential disruption of
distribution capabilities, including service issues with
third-party shippers; our dependence on relationships with sales
representatives and service technicians to retain customers and
develop business; risks of selling private label products,
including the risk of adversely affecting our relationships with
suppliers; adverse changes in supplier rebates or other purchasing
incentives; the risk of technological and market obsolescence for
the products we sell; the risk of failing to innovate and develop
new and enhanced software and e-services products; our dependence
on positive perceptions of Patterson’s reputation; risks associated
with illicit human use of pharmaceutical products we distribute;
risks inherent in acquiring and disposing of assets or other
businesses and risks inherent in integrating acquired businesses;
turnover or loss of key personnel or highly skilled employees;
risks associated with information systems, software products and
cyber-security attacks; risks inherent in our growing use of AI
systems to automate processes and analyze data; adverse impacts of
wide-spread public health concerns as we experienced with the
COVID-19 pandemic and may experience in the future; risks related
to climate change; our ability to comply with restrictive covenants
and other limits in our credit agreement; the risk that our
governing documents and Minnesota law may discourage takeovers and
business combinations; the effects of the highly competitive dental
and animal health supply markets in which we compete; the effects
of consolidation within the dental and animal health supply
markets; risks from the formation or expansion of GPOs, provider
networks and buying groups that may place us at a competitive
disadvantage; exposure to the risks of the animal production
business, including changing consumer demand, the cyclical
livestock market, weather conditions, the availability of natural
resources and other factors outside our control, and the risks of
the companion animal business, including the possibility of disease
adversely affecting the pet population; exposure to the risks of
the health care industry, including changes in demand due to
political, economic and regulatory influences and other factors
outside our control; increases in over-the-counter sales and
e-commerce options; risks of litigation and government inquiries
and investigations, including the diversion of management’s
attention, the cost of defending against such actions, the
possibility of damage awards or settlements, fines or penalties, or
equitable remedies (including but not limited to the revocation of
or non-renewal of licenses) and inherent uncertainty; failure to
comply with health care fraud or other laws and regulations; change
and uncertainty in the health care industry; failure to comply with
existing or future U.S. or foreign laws and regulations including
those governing the distribution of pharmaceuticals and controlled
substances; failure to comply with evolving data privacy laws and
regulations; tax legislation; risks inherent in international
operations, including currency fluctuations; and uncertain
macro-economic conditions, including inflationary pressures.
The order in which these factors appear should not be construed
to indicate their relative importance or priority. We caution that
these factors may not be exhaustive, accordingly, any
forward-looking statements contained herein should not be relied
upon as a prediction of actual results.
You should carefully consider these and other relevant factors,
including those risk factors in Part I, Item 1A, (“Risk Factors”)
in our most recent Form 10-K and information which may be contained
in our other filings with the U.S. Securities and Exchange
Commission, or SEC, when reviewing any forward-looking
statement.
Investors should understand it is impossible to predict or
identify all such factors or risks. As such, you should not
consider the foregoing list, or the risks identified in our SEC
filings, to be a complete discussion of all potential risks or
uncertainties.
Any forward-looking statement made by us in this press release
is based only on information currently available to us and speaks
only as of the date on which it is made. We do not undertake any
obligation to release publicly any revisions to any forward-looking
statements, whether written or oral, that may be made from time to
time, whether as a result of new information, future developments
or otherwise.
PATTERSON COMPANIES,
INC.
CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS
(In thousands, except per
share amounts)
(Unaudited)
Three Months Ended
July 27, 2024
July 29, 2023
Net sales
$
1,541,742
$
1,576,745
Gross profit
312,609
319,055
Operating expenses
283,240
280,833
Operating income
29,369
38,222
Other income (expense):
Other income, net
1,714
11,901
Interest expense
(13,223
)
(9,512
)
Income before taxes
17,860
40,611
Income tax expense
4,221
9,481
Net income
13,639
31,130
Net loss attributable to noncontrolling
interests
(76
)
(104
)
Net income attributable to Patterson
Companies, Inc.
$
13,715
$
31,234
Earnings per share attributable to
Patterson Companies, Inc.:
Basic
$
0.16
$
0.33
Diluted
$
0.15
$
0.32
Weighted average shares:
Basic
88,127
95,544
Diluted
88,645
96,190
Dividends declared per common share
$
0.26
$
0.26
PATTERSON COMPANIES,
INC.
CONDENSED CONSOLIDATED BALANCE
SHEETS
(In thousands)
(Unaudited)
July 27, 2024
April 27, 2024
ASSETS
Current assets:
Cash and cash equivalents
$
148,079
$
114,462
Receivables, net
442,342
547,287
Inventory, net
849,504
782,898
Prepaid expenses and other current
assets
322,185
334,116
Total current assets
1,762,110
1,778,763
Property and equipment, net
226,151
229,081
Operating lease right-of-use assets,
net
124,473
122,295
Goodwill and identifiable intangibles,
net
340,166
349,589
Investments
167,386
166,320
Long-term receivables, net and other
254,472
250,684
Total assets
$
2,874,758
$
2,896,732
LIABILITIES AND STOCKHOLDERS'
EQUITY
Current liabilities:
Accounts payable
$
656,977
$
745,375
Other accrued liabilities
223,025
245,610
Operating lease liabilities
33,643
32,815
Current maturities of long-term debt
123,875
122,750
Borrowings on revolving credit
320,000
186,000
Total current liabilities
1,357,520
1,332,550
Long-term debt
327,153
328,911
Non-current operating lease
liabilities
94,261
92,464
Other non-current liabilities
143,323
141,075
Total liabilities
1,922,257
1,895,000
Stockholders' equity
952,501
1,001,732
Total liabilities and stockholders'
equity
$
2,874,758
$
2,896,732
PATTERSON COMPANIES,
INC.
CONDENSED CONSOLIDATED
STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
Three Months Ended
July 27, 2024
July 29, 2023
Operating activities:
Net income
$
13,639
$
31,130
Adjustments to reconcile net income to net
cash used in operating activities:
Depreciation and amortization
22,750
21,033
Stock-based compensation
8,060
7,015
Non-cash losses (gains) and other, net
1,745
2,268
Change in assets and liabilities:
Receivables
(140,656
)
(154,602
)
Inventory
(65,292
)
(114,323
)
Accounts payable
(91,995
)
(11,093
)
Accrued liabilities
(22,698
)
(21,715
)
Other changes from operating activities,
net
(10,523
)
(13,079
)
Net cash used in operating activities
(284,970
)
(253,366
)
Investing activities:
Additions to property and equipment and
software
(13,507
)
(17,087
)
Collection of deferred purchase price
receivables
271,834
242,013
Payments related to acquisitions, net of
cash acquired
—
(1,108
)
Net cash provided by investing
activities
258,327
223,818
Financing activities:
Dividends paid
(23,312
)
(25,432
)
Repurchases of common stock
(50,000
)
(29,508
)
Payments on long-term debt
(750
)
(750
)
Draw on revolving credit
134,000
31,000
Other financing activities
(1,151
)
1,574
Net cash provided by (used in) financing
activities
58,787
(23,116
)
Effect of exchange rate changes on
cash
1,473
1,568
Net change in cash and cash
equivalents
33,617
(51,096
)
Cash and cash equivalents at beginning of
period
114,462
159,669
Cash and cash equivalents at end of
period
$
148,079
$
108,573
PATTERSON COMPANIES,
INC.
SALES SUMMARY
(Dollars in thousands)
(Unaudited)
July 27, 2024
July 29, 2023
Total
Sales
Growth
Foreign
Exchange
Impact
Net Interest Rate Swap
Internal Sales
Growth
Three Months
Ended
Consolidated net sales
Consumable
$
1,278,413
$
1,315,725
(2.8
)%
—
%
—
%
(2.8
)%
Equipment
159,286
163,971
(2.9
)
(0.2
)
—
(2.7
)
Value-added services and other
104,043
97,049
7.2
(0.1
)
10.7
(3.4
)
Total
$
1,541,742
$
1,576,745
(2.2
)%
(0.1
)%
0.7
%
(2.8
)%
Dental
Consumable
$
344,117
$
352,047
(2.3
)%
(0.2
)%
—
%
(2.1
)%
Equipment
133,858
137,549
(2.7
)
(0.3
)
—
(2.4
)
Value-added services and other
72,382
77,704
(6.8
)
(0.1
)
—
(6.7
)
Total
$
550,357
$
567,300
(3.0
)%
(0.2
)%
—
%
(2.8
)%
Animal Health
Consumable
$
934,296
$
963,678
(3.0
)%
—
%
—
%
(3.0
)%
Equipment
25,428
26,422
(3.8
)
—
—
(3.8
)
Value-added services and other
22,689
20,890
8.6
0.3
—
8.3
Total
$
982,413
$
1,010,990
(2.8
)%
—
%
—
%
(2.8
)%
Corporate
Value-added services and other
$
8,972
$
(1,545
)
n/m
—
%
n/m
(0.2
)%
Total
$
8,972
$
(1,545
)
n/m
—
%
n/m
(0.2
)%
PATTERSON COMPANIES,
INC.
OPERATING INCOME BY
SEGMENT
(In thousands)
(Unaudited)
Three Months Ended
July 27, 2024
July 29, 2023
Operating income (loss)
Dental
$
27,058
$
38,670
Animal Health
25,367
29,693
Corporate
(23,056
)
(30,141
)
Total
$
29,369
$
38,222
PATTERSON COMPANIES,
INC.
RECONCILIATION OF GAAP TO
NON-GAAP MEASURES
(Dollars in thousands, except
per share amounts)
(Unaudited)
For the three months ended July 27,
2024
GAAP
Deal amortization
Interest rate swap
Non-GAAP
Net sales
$
1,541,742
$
—
$
(3,755
)
$
1,537,987
Gross profit
312,609
—
(3,755
)
308,854
Operating expenses
283,240
(9,639
)
—
273,601
Operating income
29,369
9,639
(3,755
)
35,253
Other income (expense), net
(11,509
)
—
3,755
(7,754
)
Income before taxes
17,860
9,639
—
27,499
Income tax expense
4,221
2,305
—
6,526
Net income
13,639
7,334
—
20,973
Net loss attributable to noncontrolling
interests
(76
)
—
—
(76
)
Net income attributable to Patterson
Companies, Inc.
$
13,715
$
7,334
$
—
$
21,049
Diluted earnings per share attributable to
Patterson Companies, Inc.*
$
0.15
$
0.08
$
—
$
0.24
Gross margin
20.3
%
20.1
%
Operating margin
1.9
%
2.3
%
Effective tax rate
23.6
%
23.7
%
For the three months ended July 29,
2023
GAAP
Deal amortization
Interest rate swap
Non-GAAP
Net sales
$
1,576,745
$
—
$
6,775
$
1,583,520
Gross profit
319,055
—
6,775
325,830
Operating expenses
280,833
(9,626
)
—
271,207
Operating income
38,222
9,626
6,775
54,623
Other income (expense), net
2,389
—
(6,775
)
(4,386
)
Income before taxes
40,611
9,626
—
50,237
Income tax expense
9,481
2,304
—
11,785
Net income
31,130
7,322
—
38,452
Net loss attributable to noncontrolling
interests
(104
)
—
—
(104
)
Net income attributable to Patterson
Companies, Inc.
$
31,234
$
7,322
$
—
$
38,556
Diluted earnings per share attributable to
Patterson Companies, Inc.*
$
0.32
$
0.08
$
—
$
0.40
Gross margin
20.2
%
20.6
%
Operating margin
2.4
%
3.4
%
Effective tax rate
23.3
%
23.5
%
* May not sum due to rounding
PATTERSON COMPANIES,
INC.
FREE CASH FLOW
(In thousands)
(Unaudited)
Three Months Ended
July 27, 2024
July 29, 2023
Net cash used in operating activities
$
(284,970
)
$
(253,366
)
Additions to property and equipment and
software
(13,507
)
(17,087
)
Collection of deferred purchase price
receivables
271,834
242,013
Free cash flow
$
(26,643
)
$
(28,440
)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240828954044/en/
INVESTOR CONTACT: John M. Wright, Investor Relations
TEL: 651.686.1364 EMAIL:
investor.relations@pattersoncompanies.com MEDIA CONTACT:
Patterson Corporate Communications TEL: 651.905.3349
EMAIL: corporate.communications@pattersoncompanies.com
WEB: pattersoncompanies.com
Patterson Companies (NASDAQ:PDCO)
Historical Stock Chart
From Nov 2024 to Dec 2024
Patterson Companies (NASDAQ:PDCO)
Historical Stock Chart
From Dec 2023 to Dec 2024